Shine-On BioMedical Co., Ltd.
Update：2026/08/06
Industries
Main Industry
Biotechnology
Main Product/Service
The company’s pipeline features novel therapeutic candidates, such as precision-engineered exosomes for targeted drug delivery and nanometer-scale trispecific antibodies that engage T cells. These next-generation biologics are designed to improve the spec
Founded Year
2021
Unified Business No.
90841519
Status
Active
Number of Employees
0
Total Paid-in
Capital
498,000,000 (NT$)
Location of Company
Taiwan
, Taichung City
Exit Status
Emerging Stock Exchange(2022)
Information such as company name, company status, responsible person, year of establishment, paid-in capital, and registered address is sourced from the Commercial and Industrial Registration Office of the Ministry of Economic Affairs; listing status includes emerging stock, M&A, and IPO; overseas development is provided by the startup itself.
Notice: This data is compiled from public sources for reference only. We have no direct affiliation with the company and are not their contact person.
Exclusive content for members
Members-only content. Please log in to access.
About the Company
The company has developed a series of first-in-human novel drugs that are based on the innovative technology platforms of “targeted exosome for drug delivery” and “trispecific T-cell engager antibody”. The Company has various technical patents for the exosomes and multi-specific antibody drugs. ShineOn collaborated with worldwide renown research institutes, international capable CDMO/CRO companies and professional expert consulting groups to create new biological drugs to treat patients with cancers. According to the Cortellis database, ShineOn is ranked among the top ten companies worldwide for developing "next-generation" targeted exosome therapeutic drugs and multi-specific antibody drugs.
The company was successfully listed on the Emerging Stock Market of Taipei Exchange (code 6926) in November 2022.
The company was successfully listed on the Emerging Stock Market of Taipei Exchange (code 6926) in November 2022.
